VANCOUVER, British Columbia, May 14, 2026
Zymeworks Inc. announced that its Board of Directors has approved a new 2026 share repurchase program authorizing the company to repurchase up to $125 million of its outstanding common stock, reflecting the biotechnology company’s continued focus on disciplined capital allocation, shareholder value creation, and long-term financial flexibility. The move highlights growing confidence in the company’s financial position as it continues advancing a broad pipeline of multifunctional biotherapeutics targeting cancer, inflammation, and autoimmune diseases.
The newly authorized repurchase initiative replaces Zymeworks’ previous 2025 share repurchase program, under which the company repurchased approximately 4.2 million shares for a total of $102.3 million, representing an average purchase price of $24.36 per share. According to the company, the new program demonstrates its commitment to balancing strategic investment in research and development while also returning value to shareholders through efficient capital management strategies.
Zymeworks stated that the share repurchase program will be funded through the company’s strong balance sheet and may include open market purchases or transactions conducted under Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act. The company emphasized that repurchase timing and transaction size will depend on market conditions, stock price performance, corporate considerations, and regulatory requirements.
Zymeworks Strengthens Long-Term Biotech Strategy
Company leadership described the repurchase authorization as part of a broader long-term strategy focused on maximizing shareholder returns while preserving flexibility to continue investing in innovative biotechnology programs and strategic opportunities. Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, stated that the initiative supports disciplined financial management while maintaining momentum across the company’s expanding biotherapeutics pipeline.
Advertisement
As of May 13, 2026, Zymeworks reported approximately 73 million outstanding common shares, highlighting the scale of the approved repurchase initiative relative to the company’s current market structure. Industry analysts noted that biotechnology companies implementing large-scale repurchase programs are often signaling confidence in long-term business fundamentals, pipeline development potential, and future cash generation capabilities.
Zymeworks has increasingly evolved into a diversified biotechnology company focused on both innovative drug development and healthcare asset management. In addition to advancing proprietary therapies, the company continues building royalty and licensing revenue streams designed to strengthen long-term financial sustainability.
Healthcare investors continue to closely monitor biotechnology capital allocation strategies as market conditions remain highly competitive across oncology, immunology, and precision medicine sectors. Share repurchase programs are increasingly viewed as important tools for balancing growth investment with shareholder-focused financial management.
Oncology and Biotherapeutics Pipeline Continues Expanding
Zymeworks is recognized for its expertise in developing multifunctional biotherapeutics and antibody-based therapies targeting difficult-to-treat diseases. The company engineered and developed Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody developed using its proprietary Azymetric™ technology platform.
The company has established strategic licensing agreements with major pharmaceutical partners including BeOne Medicines and Jazz Pharmaceuticals for the development and commercialization of zanidatamab across multiple international markets. Zymeworks also continues advancing a diverse pipeline of antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in oncology and immune-related diseases.
Executives emphasized that the company’s integrated drug development engine and proprietary therapeutic platforms provide flexibility to engineer highly differentiated antibody-based therapies capable of addressing significant unmet medical needs. Zymeworks noted that strategic collaborations with global biopharmaceutical companies remain central to its long-term commercialization and innovation strategy.
Biotech Financial Strategy Gains Importance
The biotechnology sector continues experiencing increased focus on financial discipline, capital efficiency, and sustainable pipeline development as investors prioritize companies capable of balancing innovation with long-term value creation. Analysts noted that companies with strong cash positions and strategic flexibility are better positioned to navigate evolving market conditions and support future product development opportunities.
Zymeworks stated that the repurchase authorization reflects confidence in its operational strategy, financial foundation, and long-term biotechnology growth potential. The company added that maintaining investment capacity for research, pipeline expansion, and future strategic partnerships remains a key component of its overall corporate strategy as it continues developing advanced therapies for cancer and immune-mediated diseases.
Source: Zymeworks press release
